Literature DB >> 26985452

Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1.

Pavithra Viswanath1, Sabrina M Ronen1.   

Abstract

Mutations in isocitrate dehydrogenase 1 (IDH1) characterize most adult low-grade gliomas. Mutant IDH1 catalyzes production of the oncometabolite 2-hydroxyglutarate (2-HG). We recently discovered that the IDH1 mutation also reprograms pyruvate metabolism in a 2-HG-dependent manner, and reprogramming of pyruvate metabolism is essential for cell proliferation in mutant IDH1 glioma cells.

Entities:  

Keywords:  2-HG; IDH1; gliomas; metabolic reprogramming; pyruvate dehydrogenase

Year:  2015        PMID： 26985452      PMCID： PMC4789071          DOI： 10.1080/23723556.2015.1077922

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.

Authors:  Jose L Izquierdo-Garcia; Pavithra Viswanath; Pia Eriksson; Larry Cai; Marina Radoul; Myriam M Chaumeil; Michael Blough; H Artee Luchman; Samuel Weiss; J Gregory Cairncross; Joanna J Phillips; Russell O Pieper; Sabrina M Ronen
Journal:  Cancer Res       Date:  2015-06-04       Impact factor: 12.701

2.  D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.

Authors:  Masato Sasaki; Christiane B Knobbe; Momoe Itsumi; Andrew J Elia; Isaac S Harris; Iok In Christine Chio; Rob A Cairns; Susan McCracken; Andrew Wakeham; Jillian Haight; Annick You Ten; Bryan Snow; Takeshi Ueda; Satoshi Inoue; Kazuo Yamamoto; Myunggon Ko; Anjana Rao; Katharine E Yen; Shinsan M Su; Tak Wah Mak
Journal:  Genes Dev       Date:  2012-08-27       Impact factor: 11.361

3.  Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate.

Authors:  Sarah J Nelson; John Kurhanewicz; Daniel B Vigneron; Peder E Z Larson; Andrea L Harzstark; Marcus Ferrone; Mark van Criekinge; Jose W Chang; Robert Bok; Ilwoo Park; Galen Reed; Lucas Carvajal; Eric J Small; Pamela Munster; Vivian K Weinberg; Jan Henrik Ardenkjaer-Larsen; Albert P Chen; Ralph E Hurd; Liv-Ingrid Odegardstuen; Fraser J Robb; James Tropp; Jonathan A Murray
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

4.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Authors:  Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 12.779

5.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

Review 6.  Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies.

Authors:  Liem Minh Phan; Sai-Ching Jim Yeung; Mong-Hong Lee
Journal:  Cancer Biol Med       Date:  2014-03       Impact factor: 4.248

7.  Metabolic reprogramming in mutant IDH1 glioma cells.

Authors:  Jose L Izquierdo-Garcia; Pavithra Viswanath; Pia Eriksson; Myriam M Chaumeil; Russell O Pieper; Joanna J Phillips; Sabrina M Ronen
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

8.  Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology.

Authors:  Gopinath Sutendra; Evangelos D Michelakis
Journal:  Front Oncol       Date:  2013-03-07       Impact factor: 6.244

Review 9.  IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.

Authors:  Hui Yang; Dan Ye; Kun-Liang Guan; Yue Xiong
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 13.801

10.  Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.

Authors:  Jose L Izquierdo-Garcia; Larry M Cai; Myriam M Chaumeil; Pia Eriksson; Aaron E Robinson; Russell O Pieper; Joanna J Phillips; Sabrina M Ronen
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240
  10 in total
  2 in total

1.  Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.

Authors:  Risheng Yang; Yuanlin Zhao; Yu Gu; Ying Yang; Xing Gao; Yuan Yuan; Liming Xiao; Jin Zhang; Chao Sun; Han Yang; Junhui Qin; Jing Li; Feng Zhang; Lijun Zhang; Jing Ye
Journal:  Oncogene       Date:  2020-08-27       Impact factor: 9.867

Review 2.  Prospects of biological and synthetic pharmacotherapies for glioblastoma.

Authors:  David B Altshuler; Padma Kadiyala; Felipe J Nuñez; Fernando M Nuñez; Stephen Carney; Mahmoud S Alghamri; Maria B Garcia-Fabiani; Antonela S Asad; Alejandro J Nicola Candia; Marianela Candolfi; Joerg Lahann; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2020-01-20       Impact factor: 4.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.